The clock is ticking on Provenge; Dendreon Corp. ($DNDN)

Dendreon Corp. (NASDAQ:DNDN) is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development, commercialization, and manufacturing of novel therapeutics that may significantly improve cancer treatment options for patients. Dendreon's first product, PROVENGE® (sipuleucel-T), is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. 

A North America Equity Research report by JP Morgan released last week evalutes the impact of the Independent Data Monitoring Committee's unanimous recommendation to unblind "the Phase 3 trial of Zytiga in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) patients – the market currently served by DNDN’s Provenge." 

The report states:

"Ultimately we believe CRPC patients are likely to receive several drugs (including DNDN’s Provenge and JNJ’s Zytiga) during the course of their disease (as none of them are “cures”) and note that DNDN is currently conducting a sequencing trial with Provenge and Zytiga (data expected later this year). Today’s news doesn’t impact our valuation as this development was already built into our assumptions. While our overall view is unchanged, we believe the clock is ticking on DNDN to cement use of Provenge into CRPC treatment practice before approval of other drugs in the pre-chemo setting."

Read the full report below. 

JP Morgan Dendreon Report

View more documents from DailyDoseEquities